Prognostic factors in prostate cancer

Diagnostic Pathology

Volumn 1, Issue 1, 2006, Pages

  Buhmeida, A ^a   Pyrhonen S ^a   Laato, M ^a   Collan, Y ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34047125906     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-1-4     Document Type: Review

References (183)

1. Badalament RA, Drago JR: Prostate cancer. Dis Mon 1991, 37:199-268.
2. Hanchette CL, Schwartz GG: Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70:2861-2869.
3. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics, 2001. CA Cancer J Clin 2001, 51(1):15-36.
4. Shi XB, Gumerlock PH, deVere White RW: Molecular biology of prostate cancer. World J Urol 1996, 14:318-328.
5. Vogel W, Maier C, Paiss T: Prostate cancer. Cooper DN (editor) 2003, 4:743-757.
6. Foley R, Hollywood D, Lawler M: Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease. Endocr Relat Cancer 2004, 11(3):477-88.
7. Paris PL, Andaya A, Fridlyand J, et al.: Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumours. Hum Mol Genet 2004, 13:1303-1313.
8. Huncharek M, Muscat J: Genetic characteristics of prostate cancer. Cancer Epidemiol Biomarkers Prev 1995, 4:681-687.
9. Nupponen N, Visakorpi T: Molecular cytogenetics of prostate cancer. Microsc Res Tech 2000, 51:456-463.
10. Pan Y, Lui W, Nupponen N, Larsson C, Isola J, Visakorpi T, Bergerheim U, Kytola S: 5q11, 8p11 and 10q22 are recurrent chromosomal breakpoints in prostate cancer cell lines. Genes Chromosomes Cancer 2001, 30:187-195.
11. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, et al.: Patterns of progression in prostate cancer. Lancet 1986, 1:60-63.
12. Carter HB, Partin AW, Coffey DS: Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. J Urol 1989, 142(5):1338-1341.
13. Kwast , van der TH: Prognostic factors and reporting of prostate carcinoma in radical prostatectomy specimens. Update in pathology. European Congress of Pathology,. 3-8 Sept, 2005 Paris:475-478.
14. Smith JA Jr, Cho YH: Management of stage A prostate cancer. Urol Clin North Am 1990, 17:769-777.
15. Austin JP, Convery K: Age race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol 1993, 16:140-145.
16. Gronberg H, Damber JE, Jonsson H, Lenner P: Patient age as a prognostic factor in prostate cancer. J Urol 1994, 152:892-895.
17. Herold DM, Hanlon AL, Movsas B, Hanks GE: Age-related prostate cancer metastases. Urology 1998, 51:985-990.
18. Obek C, Lai S, Sadek S, Civantos F, Soloway MS: Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology 1999, 54(3):533-538.
19. Freedland SJ, Presti JC, Kane CJ, Aronson WJ, Terris MK, Dorey F, et al.: Do younger men have better biochemical outcomes after radical prostatectomy? Urology 2004, 63(3):518-22.
20. Partin AW, Epstein JI, Cho KR, Gittelsohn AM, Walsh PC: Morphometric measurement of tumour volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol 1989, 141:341-345.
21. Terris MK, McNeal JE, Stamey TA: Estimation of prostate cancer volume by transrectal ultrasound imaging. J Urol 1992, 147:855-857.
22. Dietrick DD, McNeal JE, Stamey TA: Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology 1995, 45:987-992.
23. Terris MK, Haney DJ, Johnstone IM, McNeal JE, Stamey TA: Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology 1995, 45:75-80.
24. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA: Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol 1990, 14:240-247.
25. Epstein JI, Carmichael M, Partin AW, Walsh PC: Is tumour volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993, 149:1478-1481.
26. Bostwick DG, Graham SD, Napalkov P, Abrahamsson PA, di Sant'agnese PA, Algaba F, et al.: Staging of early prostate cancer: a proposed tumour volume-based prognostic index. Urology 1993, 41:403-411.
27. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA: Patterns of progression in prostate cancer. Lancet 1986, 1:60-63.
28. Salomon L, Levrel O, Anastasiadis AG, Irani J, De La Taille A, Saint F, et al.: Prognostic significance of tumour volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. Eur Urol 2003, 3(1):39-44.
29. Kikuchi E, Scardino PT, Wheeler TM, Slawin KM, Ohori M: Is tumour volume an independent prognostic factor in clinically localized prostate cancer? J Urol 2004, 172(2):508-11.
30. Bostwick DG: Grading prostate cancer. Am J Clin Pathol 1994, 102(1):S38-56.
31. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50(3):125-8.
32. Humphrey PA: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004, 17(3):292-306.
33. Bostwick DG: Grading prostate cancer. Am J Clin Pathol 1994, 102(4 Suppl 1):S38-56.
34. Humphrey PA: Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004, 17(3):292-306.
35. Djavan B, Kadesky K, Klopukh B, Marberger M, Roehrborn CG: Gleason scores from prostate biopsies obtained with 18-gauge biopsy needles poorly predict Gleason scores of radical prostatectomy specimens. Eur Urol 1998, 33:261-270.
36. Lattouf JB, Saad F: Gleason score on biopsy: is it reliable for predicting the final grade on pathology? BJU Int 2002, 90(7):694-8.
37. Koksal IT, Ozcan F, Kadioglu TC, Esen T, Kilicaslan I, Tunc M: Discrepancy between Gleason scores of biopsy and radical prostatectomy specimens. Eur Urol 2000, 37:670-674.
38. Shen BY, Tsui KH, Chang PL, Chuang CK, Hsieh ML, Huang ST, et al.: Correlation between the Gleason scores of needle biopsies and radical prostatectomy specimens. Chang Gung Med J 2003, 26(12):919-24.
39. Epstein JI, Steinberg GD, The significance of low-grade prostate cancer on needle biopsy: A radical prostatectomy study of tumour grade, volume, and stage of the biopsied and multifocal tumour. Cancer 1990, 66:1927-1932.
40. Gleason DF, The veterans adminstrative cooperative urologic research group: Histological grading and clinical staging of prostatic carcinoma. Urologic Pathology: The prostate. Philadelphia: Lea and Febiger 1977:171-198.
41. Sogani PC, Israel A, Lieberman PH, Lesser ML, Whitmore WF: Gleason grading of prostate cancer: a predictor of survival. Urology 1985, 25:223-227.
42. Rioux-Leclercq NC, Chan DY, Epstein JI: Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma. Urology 2002, 60(4):666-9.
43. Cheng L, Koch MO, Juliar BE, Daggy JK, Foster RS, Bihrle R, Gardner TA: The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J Clin Oncol 2005, 23(13):2911-7.
44. Partin AW, Too J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150(1):110-4.
45. Oesterling JE, Brendler CB, Epstein JI, Kimball AW, Walsh PC: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate, J Urol 1987, 138:92-98.
46. Fowler JE, Mills SE: Operable prostatic carcinoma: correlations among clinical stage, pathological stage, gleason histological score and early disease-free survival, J Urol 1985, 133:49-52.
47. Epstein JI, Carmichael M, Walsh PC: Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumour volume, grade and margins of resection to prognosis. J Urol 1993, 149:1040-1045.
48. Theiss M, Wirth MP, Manseck A, Frohmuller HG: Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate 1995, 27:13-17.
49. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT: Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995, 154:1818-1824.
50. Wheeler TM, Dillioglugil O, Kattan MW, Arakawa A, Soh S, Suyama K, et al.: Clinical and pathological significance of the level and extent of capsular invasion in clinical stage TI-2 prostate cancer. Hum Pathol 1998, 29:856-862.
51. Deliveliotis CH, Varkarakis J, Trakas N, Louras G, Giannakopoulos S, Skolarikos A, et al.: Influence of preoperative vesicle biopsy on the decision for radical prostatectomy. Int Urol Nephrol 1999, 31:83-87.
52. Salomon L, Anastasiadis AG, Johnson CW, McKiernan JM, Goluboff ET, Abbou CC, et al.: Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology 2003, 62(2):304-9.
53. Epstein JI, Carmichael MJ, Pizov G, Walsh PC: Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993, 150:135-141.
54. Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV: Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004, 63(2):333-6.
55. Debras B, Guillonneau B, Bougaran J, Chambon E, Vallancien G: Prognostic significance of seminal vesicle invasion on the radical prostatectomy specimen. Rationale for seminal vesicle biopsies. Eur Urol 1998, 33:271-277.
56. Freedland SJ, Aronson WJ, Presti JC, Amling CL, Terris MK, Trock B, et al.: Predictors of prostate-specific antigen progression among men with seminal vesicle invasion at the time of radical prostatectomy. Cancer 2004, 15;100(8):1633-8.
57. McNeal JE: Regional morphology and pathology of the prostate. Am J Clin Pathol 1968, 49:347-357.
58. McNeal J: The zonal anatomy of the prostate. Prostate 1981, 2:35-49.
59. McNeal JE, Redwine EA, Freiha FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988, 12:897-906.
60. Greene DR, Wheeler TM, Egawa S, Dunn JK, Scardino PT: A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol 1991, 146:1069-1076.
61. Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, et al.: Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology 2003, 62(1):79-85.
62. Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, et al.: Pathological parameters of radical prostatectomy for clinical stages Tic versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumours. J Urol 2002, 168(2):519-24.
63. Moore RA: Morphology of small prostatic carcinomas. J Urol 1935, 33:224-235.
64. Miller GJ, Cygan JM: Diagnostic correlations with whole mounts of radical prostatectomy specimens. Monogr Pathol 1992, 34:183-197.
65. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, McNeal JE, Miller GJ, et al.: Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Scand J Urol Nephrol Suppl 1994, 162:12-13.
66. Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA: Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol 2002, 41(4):363-71.
67. Hammerer P, Huland H, Sparenberg A: Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol 1992, 22:281-287.
68. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M: Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol 1999, 5(3):139-42.
69. Diamond DA, Berry SJ, Umbricht C, Jewett HJ, Coffey DS: Computerized image analysis of nuclear shape as a prognostic factor for prostatic cancer. Prostate 1982, 3(4):321-32.
70. Diamond DA, Berry SJ, Jewett HJ, Eggleston JC, Coffey DS: A new method to assess metastatic potential of human prostate cancer: relative nuclear roundness. J Urol 1982, 128:729-734.
71. Epstein JI, Berry SJ, Eggleston JC: Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. Cancer 1984, 54:666-671.
72. Clark TD, Askin FB, Bagnell CR: Nuclear roundness factor: a quantitative approach to grading in prostatic carcinoma, reliability of needle biopsy tissue, and the effect of tumour stage on usefulness. Prostate 1987, 10:199-206.
73. Eichenberger T, Mihatsch MJ, Oberholzer M, Gschwind R, Rutishauser G: Are nuclear shape factors good predictors of the disease course in patients with carcinoma of the prostate? Prog Clin Biol Res 1987, 243A:533-537.
74. Mohler JL, Partin AW, Epstein JI, Lohr WD, Coffey DS: Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections. J Urol 1988, 139:1085-1090.
75. Partin AW, Walsh AC, Pitcock RV, Mohler JL, Epstein JI, Coffey DS: A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis. J Urol 1989, 142:1254-1258.
76. Partin AW, Steinberg GD, Pitcock RV, Wu L, Piantadosi S, Coffey DS, et al.: Use of nuclear morphometry, Gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. Cancer 1992, 70:161-168.
77. Aragona F, Franco V, Rodolico V, Dardanoni G, Cabibi D, Melloni D, et al.: Interactive computerized morphometric analysis for the differential diagnosis between dysplasia and well differentiated adenocarcinoma of the prostate. Urol Res 1989, 17:35-40.
78. Vesalainen S, Lipponen P, Talja M, Kasurinen J, Syrjanen K: Nuclear morphometry is of independent prognostic value only in TI prostatic adenocarcinomas. Prostate 1995, 27:110-117.
79. Martinez-Jabaloyas JM, Ruiz-Cerda JL, Hernandez M, Jimenez A, Jimenez-Cruz F: Prognostic value of DNA ploidy and nuclear morphometry in prostate cancer treated with androgen deprivation. Urology 2002, 59(5):715-20.
80. Martinez Jabaloyas JM, Jimenez Sanchez A, Ruiz Cerda JL, Sanz Chinesta S, Sempere A, Jimenez Cruz JF: Prognostic value of DNA ploidy and nuclear morphometry in metastatic prostate cancer. Actos Urol Esp 2004, 28(4):298-307.
81. Maffini MV, Ortega HH, Stoker C, Giardina RH, Luque EH, Munoz de Toro MM: Bcl-2 correlates with tumour ploidy and nuclear morphology in early stage prostate carcinoma, fine needle aspiration biopsy study. Pathol Res Pract 2001, 197(7):487-92.
82. Buhmeida A, Kuopio T, Collan Y: Nuclear size and shape in fine needle aspiration biopsy samples of the prostate. Anal Quant Cytol Histol 2000, 22(4):291-8.
83. Umbas R, Schalken JA, Aalders TW, Carter BS, Kalthaus HF, Schaafsma HE, et al.: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992, 52:5104-5109.
84. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al.: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994, 54:3929-3933.
85. Umbas R, Isaacs WB, Bringuier PP, Xue Y, Debruyne FM, Schalken JA: Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 1997, 74:374-377.
86. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Kosma VM: Alpha-catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 1999, 80:477-482.
87. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: E-cadherin expression as a marker of tumour aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53:707-713.
88. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Concer Inst 2003, 9:661-8.
89. Mita K, Nakahara M, Usui T: Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients. Int J Urol 2000, 7:321-329.
90. Figueroa JA, De-Raad S, Tadlock L, Speights VO, Rinehart JJ: Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer. J Urol 1998, 159:1379-1383.
91. Yu H, Nicar MR, Shi R, Berkel HJ, Nam R, Trachtenberg J, et al.: Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 2001, 57:471-475.
92. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor I in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997, 76(9):1115-8.
93. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 23;279(5350): 563-6.
94. Shariat SF, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM, et al.: Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. Urology 2000, 56:423-429.
95. Yu H, Bharaj B, Vassilikos EJ, Giai M, Diamandis EP: Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 2000, 59:153-161.
96. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP: Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol 1998, 152:1-9.
97. Wallen MJ, Linja M, Kaartinen K, Schleutker J, Visakorpi T: Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 1999, 189:559-563.
98. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, et al.: Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001, 51:452-459.
99. Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, Miyamoto H, Miyoshi Y, et al.: Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. Prostate 2003, 1;56(4):280-6.
100. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A. et al.: Androgen receptor activation in prostatic tumour cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 15;54(20):5474-8.
101. Sadi MV, Barrack ER: Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 1993, 71:2574-2580.
102. Magi-Galluzzi C, Xu X, Hlatky L, Hahnfeldt P, Kaplan I, Hsiao P, et al.: Heterogeneity of androgen receptor content in advanced prostate cancer. Mod Pathol 1997, 10:839-845.
103. Papadopoulos I, Rudolph P, Wirth B, Weichert Jacobsen K: p53 expression, proliferation marker Ki-S5, DNA content and serum PSA: possible biopotential markers in human prostatic cancer. Urology 1996, 48:261-268.
104. Daher R, Beaini M: Prostate-specific antigen and new related markers for prostate cancer. Clin Chem Lab Med 1998, 36:671-681.
105. Björk T, Lilja H, Christensson A: The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer. BJU Int 1999, 84:1021-1027.
106. Zagars GK: Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys 1992, 23:47-53.
107. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 5;281(17):1591-7.
108. Kuriyama M, Obata K, Miyagawa Y, Nishikawa E, Koide T, Takeda A, et al.: Serum prostate-specific antigen values for the prediction of clinical stage and prognosis in patients with prostate cancer: an analysis of 749 cases. Int J Urol 1996, 3:462-467.
109. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 2002, 167(2):528-34.
110. Hellenbrand M, Bastian M, Steiner M, Zingler C, Muller M, Wolff J, et al.: Serum to urinary prostate specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer. Anticancer Res 2000, 20:4995-4996.
111. D'Amico AV, Chen MH, Roehl KA, Catalona WJ: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004, 351:125-35.
112. Roach M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, et al.: Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 2000, 1;47:609-615.
113. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW: CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998, 160:459-465.
114. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, et al.: Significance of tumour angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994, 44:869-875.
115. Borre M, Offersen BV, Nerstrom B: Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998, 78:940-944.
116. Halvorsen O, Haukaas S, Hoisaeter P, Akslen L: Independent prognostic importance of microvesel density in clinically localized prostate cancer. Anticancer Res 2000, 20:3791-3799.
117. Rubin MA, Buyyounouski M, Bagiella E, Sharir S, Neugut A, Benson M, et al.: Microvessel density in prostate cancer: lack of correlation with tumour grade, pathologic stage, and clinical outcome. Urology 1999, 53:542-547.
118. Strohmeyer D, Rossing C, Strauss F, Bauerfeind A, Kaufmann O, Loening S: Tumour angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate 2000, 42:26-33.
119. Gettman MT, Pacelli A, Slezak J, Bergstralh EJ, Blute M, Zincke H, Bostwick DG: Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology 1999, 54:479-485.
120. Krupski T, Petroni GR, Frierson HFJr, Theodorescu JU: Microvessel density, p53, retinoblastoma, and chromogranin A immuno-histochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 2000, 55:743-749.
121. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB: Determining prognosis of clinically localized prostate cancer by immuno-histochemical detection of mutant p53. Urology 1996, 47:366-369.
122. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, et al.: p53 expression and clinical outcome in prostate cancer. Br J Urol 1993, 72:778-781.
123. Shurbaji MS, Kalbfleisch JH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995, 26:106-109.
124. Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, et al.: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer. Surgery 1996, 120:159-166.
125. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 1996, 156:1511-1516.
126. Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, et al.: p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997, 89:158-165.
127. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF: p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J Urol 1997, 158:131-137.
128. Kuczyk MA, Serth J, Bokemeyer C, Machtens S, Minssen A, Bathke W, et al.: The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer 1998, 34:679-686.
129. Scherr DS, Vaughan ED, Wei J, Chung M, Felsen D, Allbright R, et al.: BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 1999, 162:12-16.
130. Barbareschi M: p27 Expression, a cyclin dependent kinase inhibitor in breast carcinoma. Adv Clin Path 1999, 3:119-127.
131. Tsuchiya A, Zhang GJ, Kanno M: Prognostic impact of cyclin-dependent kinase inhibitor p27kipl in node-positive breast cancer. J Surg Oncol 1999, 70(4):230-234.
132. Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM: Reduced expression of the cell cycle inhibitor p27Kipl in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res 1999, 59:684-688.
133. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, et al.: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999, 59:3790-3794.
134. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, et al.: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998, 159:941-945.
135. Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U: Proliferation and apoptosis associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAFI/CIPI expression. Br J Cancer 1999, 80:546-55.
136. Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N: Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res 1994, 14:2135-2140.
137. Tavares AS, Costa J, Carvalho A, Reis M: Tumour ploidy and prognosis in carcinomas of the bladder and prostate. Br J Cancer 1966, 20:438-441.
138. Epstein JI, Christensen WN, Steinberg GD, Carter HB: Comparison of DNA ploidy and nuclear size, shape and chromatin irregularity in tissue sections and smears of prostatic carcinoma. Anal Quant Cytol Histol 1990, 12:352-358.
139. Zinke H, Larson Keller JJ: Stage DI prostate cancer treated by RP and adjuvant hormonal treatment. Cancer 1992:311-323.
140. Forsslund G, Esposti PL, Nilsson B, Zetterberg A: The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992, 69:1432-1439.
141. Frankfurt OS, Chin JL, Englander LS, Greco WR, Pontes JE, Rustum YM: Relationship between DNA ploidy, glandular differentiation, and tumour spread in human prostate cancer. Cancer Res 1985, 45:1418-1423.
142. Blute ML, Nativ O, Zincke H, Farrow GM, Therneau T, Lieber MM: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumour deoxyribonucleic acid ploidy. J Urol 1989, 142: 1262-1265.
143. Forsslund G, Zetterberg A: Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma. Cancer Res 1990, 50:4281-4285.
144. Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF, Melamed MR: Flow cytometry of prostate cancer: relationship of DNA content to survival. Cancer Res 1987, 47:2504-2507.
145. Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H: Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int 2005, 95:751-756.
146. Seay TM, Blute ML, Zincke H: Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998. 159:357-364.
147. Ross JS, Figge H, Bui HX, del Rosario AD, Jennings TA, Rifkin MD, et al.: Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994, 74:2811-2818.
148. Lee SE, Currin SM, Paulson DF, Walther PJ: Flow cytometric determination of ploidy in prostatic adenocarcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 1988, 140:769-774.
149. Buhmeida A, Kuopio T, Collan Y: Influence of sampling practices on the appearance of DNA image histograms of prostate cells in FNAB samples. Anal Cell Pathol 1999, 18(2):95-102.
150. Buhmeida A, Backman H, Collan Y: DNA cytometry in diagnostic cytology of the prostate gland. Anticancer Res 2002, 22(4):2397-402.
151. Gerdes J, Schwab U. Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983, 31:13-20.
152. Cooper LS, Gillett CE, Smith P, Fentiman IS, Barnes DM: Cell proliferation measured by MIBI and timing of surgery for breast cancer. Br J Cancer 1998, 77:1502-1507.
153. Guillaud P, du Manoir S, Seigneurin D: Quantification and topographical description of Ki-67 antibody labelling during the cell cycle of normal fibroblastic (MRC-5) and mammary tumour cell lines (MCF-7). Anal Cell Pathol 1989, 1:25-39.
154. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al.: Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991, 138:867-873.
155. McLoughlin J, Foster CS, Price P, Williams G, Abel PD: Evaluation of Ki-67 monoclonal antibody as prognostic indicator for prostatic carcinoma. Br J Urol 1993, 72:92-97.
156. Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW: Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol 1996, 156:1064-1068.
157. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, et al.: Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996, 178:437-441.
158. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjanen K: Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997, 3:2410-5.
159. Ojea Calvo A, Mosteiro Cervino MJ, Dominguez Freire F, Alonso Rodrigo A, Rodriguez Iglesias B, Benavente Delgado J, et al.: The usefulness of Ki67 expression in the biopsy specimens, to predict the biochemical progresion of the prostate cancer after radical prostatectomy. Acta Urol Esp 2004, 28:650-60.
160. Montironi R, Diamanti L, Santinelli A, Scarpelli M: Computer-aided S-phase fraction determination in DNA static cytometry in breast cancer. A preliminary methodologic study on cytologic material. Anal Quant Cytol Histol 1992, 14:379-385.
161. Quinn CM, Wright NA: The clinical assessment of proliferation and growth in human tumours: evaluation of methods and applications as prognostic variables. J Pathol 1990, 160:93-102.
162. Woosley JT: Measuring cell proliferation. Arch Pathol Lab Med 1991, 115:555-557.
163. Astrom L, Weimarck A, Aldenborg F, Delle U, Hanson C, Verbiene I, et al.: S-phase fraction related to prognosis in localised prostate cancer. No specific significance of chromosome 7 gain or deletion of 7q31.1. Int J Cancer 1998, 79:553-559.
164. Bratt O, Anderson H, Bak Jensen E, Baldetorp B, Lundgren R: Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis. Urology 1996, 47:218-224.
165. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, et al.: Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1 (2):203-9.
166. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, et al.: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003, 15;63(14):4196-203.
167. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 31;415(6871):530-6.
168. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, et al.: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 19;347(25):1999- 2009.
169. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K: Delineation of prognostic biomarkers in prostate cancer. Nature 2001, 23;412(6849):822-6.
170. Magee JA, Araki T, Patil S, Ehrig T, True L, Humphrey PA, et al.: Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001, 1;61(15):5692-6.
171. Ernst T, Hergenhahn M, Kenzelmann M, Cohen CD, Bonrouhi M, Weninger A, et al.: Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. Am J Pathol 2002, 160(6):2169-80.
172. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R, Finkelstein S, et al.: Gene expression analysis of prostate cancers. Mol Carcinog 2002, 33(1):25-35.
173. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al.: Gene expression profiling identifies clinically relevant sub-types of prostate cancer. Proc Natl Acad Sci USA 2004, 20;101(3): 811-6.
174. Mikuz G: Pathology of prostate cancer. Old problems and new facts. Adv Clin Path 1997, 1(1):21-34.
175. Buhmeida A, Collan Y: Improving the value of fine needle aspiration biopsy of the prostate. Pathologica 2001, 93(3):242-3.
176. Verhagen PC, Tilanus MG, de Weger RA, van Moorselaar RJ, van den Tweel JG, Boon TA: Prognostic factors in localised prostate cancer with emphasis on the application of molecular techniques. Eur Urol 2002, 41(4):363-71.
177. Moul JW, Merseburger AS, Srivastava S: Molecular markers in prostate cancer: the role in preoperative staging. Clin Prostate Cancer 2002, 1(1):42-50.
178. Quinn DI, Henshall SM, Sutherland RL: Molecular markers of prostate cancer outcome. Eur J Cancer 2005, 41(6):858-87.
179. Quinn DI, Henshall SM, Sutherland RL: Molecular markers of prostate cancer outcome. Eur J Cancer 2005, 41(6):858-87.
180. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI: E-cadherin expression as a marker of tumour aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53(4):707-13.
181. Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P: Medical therapy of prostate cancer. A review Minerva Urol Nefrol 2005, 57(2):71-84.
182. Ryan CJ, Small EJ: Progress in detection and treatment of prostate cancer. Curr Opin Oncol 2005, 17(3):257-60.
183. Canto EI, Shariat SF, Slawin KM: Biochemical staging of prostate cancer. Urol Clin North Am 2003, 30(2):263-77.